Burning Rock Biotech (BNR) Operating Expenses (2019 - 2025)

Burning Rock Biotech's Operating Expenses history runs 7 years deep, the most recent figure standing at -$15.8 million for Q4 2025.

• In Q4 2025, Operating Expenses rose 32.63% year-over-year to -$15.8 million; the TTM figure through Dec 2025 stood at -$64.2 million (up 35.69% YoY), while the FY2025 annual figure was $65.5 million, down 33.63% from the prior year.
• Operating Expenses was -$15.8 million for Q4 2025 at Burning Rock Biotech, up from -$16.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of -$15.5 million in Q1 2025 to a low of -$56.1 million in Q4 2021.
• Historically, Operating Expenses has averaged -$34.5 million across 5 years, with a median of -$35.4 million in 2023.
• The sharpest annual moves came in 2021 and 2024: Operating Expenses slumped 154.52% in 2021, then surged 48.77% in 2024.
• A 5-year view of Operating Expenses shows it stood at -$56.1 million in 2021, then gained by 17.63% to -$46.2 million in 2022, then gained by 25.49% to -$34.4 million in 2023, then surged by 31.82% to -$23.5 million in 2024, then jumped by 32.63% to -$15.8 million in 2025.
• The last three Operating Expenses figures came in at -$15.8 million (Q4 2025), -$16.2 million (Q3 2025), and -$16.7 million (Q2 2025), per Business Quant data.